AstraZeneca Pharma India Q1 Profit Drops to Rs 37.93 Cr

New Delhi: AstraZeneca Pharma India Ltd on Monday reported a 32 per cent decline in profit after tax at Rs 37.93 crore in the June quarter, impacted by higher expenses.

The company had posted a profit after tax of Rs 55.83 crore in the corresponding quarter last fiscal year, AstraZeneca Pharma India Ltd (AZPIL) said in a regulatory filing.

Revenue from operations in the first quarter stood at Rs 682.79 crore as against Rs 526.31 crore in the corresponding period a year ago, it added.

Total expenses during the quarter were higher at Rs 641.03 crore as compared to Rs 462.49 crore in the year-ago period, the company said.

During the quarter, the company said it strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives and advanced strategic partnerships that support earlier diagnosis and broader access.

“The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India,” AstraZeneca Pharma India Ltd Country President & Managing Director Praveen Rao Akkinepally said.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)